<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03507413</url>
  </required_header>
  <id_info>
    <org_study_id>1479/2017</org_study_id>
    <nct_id>NCT03507413</nct_id>
  </id_info>
  <brief_title>Metformin Therapy in Non-diabetic AAA Patients</brief_title>
  <acronym>MetAAA</acronym>
  <official_title>A Prospective Randomized, Double Blind, Placebo-controlled, Safety and Efficacy Study of Metformin as add-on Therapy in Non-diabetic Patients With Abdominal Aortic Aneurysm (MetAAA Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective randomized, double blind, placebo-controlled, safety and efficacy study of
      metformin as add-on therapy in abdominal aortic aneurysm (AAA)

      OBJECTIVES Primary Objective

        -  To demonstrate treatment efficacy of metformin in AAA in comparison to placebo or active
           comparator, as measured by growth of the AAA maximum diameter at 12 months Secondary
           Objectives

        -  To asses inflammatory cytokines and parameters of neutrophil activation in AAA in
           response to metformin treatment by glucose

        -  insulin

        -  IL-6

        -  markers of neutrophil activation (MPO, elastase, NGAL)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      DESIGN / PHASE Prospective, single-center, randomized, parallel group, double-blind, placebo
      controlled, phase IIa study STUDY PLANNED DURATION First patient First visit Year 1 1Q

      Last patient First visit Year 2 4Q Last patient Last visit Year 3 2Q

      CENTER(S)

        -  COUNTRY(IES) 1 center in 1 country Austria PATIENTS / GROUPS 170 patients in 2 groups 85
           patients per group Randomization ratio 1:1 Stratification for hypertension, age, smoking
           habit, sex INCLUSION CRITERIA

             -  Infrarenal AAA of 4.0-5.0 cm maximum diameter EXCLUSION CRITERIA

             -  premenopausal female patients with a pregnancy possibility

             -  patients with diabetes

             -  indication for surgical AAA repair

             -  tumor malignancy &lt;1 year, chemotherapy &lt;1 year, hematological disease, chronic
                infectious disease, autoimmune disease and transplant recipients; life expectancy
                &lt;2 years

             -  contraindications for metformin, i.e. severely reduced kidney function (eGFR &lt;45
                ml/min), liver dysfunction, pancreatitis, alcohol abuse, malnutrition and
                decompensated heart failure STUDY PERIODS

             -  1-2 year recruitment

             -  1 year treatment

             -  12 month follow-up INVESTIGATIONAL DRUG

      Metformin:

      initial dose: 500 mg 1-0-1 target dose: 1000 mg 1-0-1 COMPARATIVE DRUG /CONTROL CONDITION
      Placebo Initial and target dose: tablets 1-0-1 CONCOMITANT MEDICATION Allowed (standard of
      care) EFFICACY ENDPOINTS AAA growth (in maximum diameter) over 1 year TOLERABILITY / SAFETY
      surgery when AAA&gt;5.5 cm for men, &gt; 5 cm for women Page 4 of 36 Metformin Therapy for AAA
      Department of Surgery, Division of Vascular Surgery Medical University of Vienna, Austria

      ENDPOINTS

      adverse drug reactions liver insufficiency sustained reduction of kidney function with GFR
      &lt;45 mg/dl (upontemporaryrenalinsufficiency, infections, exsiccosis, diarrhea and lactic
      acidosis, metformin treatment will only be paused)

      PHARMACOKINETIC / PHARMACODYNAMIC ENDPOINTS

        -  glucose

        -  insulin

        -  IL-6

        -  markers of neutrophil activation (MPO, elastase, NGAL)

      QUALITY OF LIFE / PHARMACOECONOMIC ENDPOINTS gastrointestinal discomfort (as assessed in the
      initial drop-out phase for patient exclusion)

      STATISTICAL METHODOLOGY Primary Endpoint AAA growth at 12 months in mm

      Null and alternative hypotheses:

      H0: Metformin does not reduce AAA growth

      H1: Metformin reduces AAA growth from mean 1.7 to 0.4 mm per year Type-I and -II errors:

      Significance: 5% Power: 80% 1.7±3.3 mm (mean±SD) without Metformin and 0.4±2.3 mm (mean±SD)
      with Metformin treatment Sample size calculation 77 per group plus 16 patients drop out Total
      N= 170 Statistical methodology Main analysis set: per protocol Primary endpoint: analysis of
      covariance adjusted for baseline AAA diameter Pharmacokinetic endpoints: analysis of
      covariance adjusted for baseline value. Parametric assumptions will be graphically checked
      with histograms.

      In case of non-normal distributions analysis of covariance will be performed after a
      logarithmic or rank transformation.

      Safety endpoints will be described by cumulative incidence curves
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2018</start_date>
  <completion_date type="Anticipated">October 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>prospective, randomized, double blind, placebo-controlled, safety and efficacy study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AAA growth over 12 months in mm</measure>
    <time_frame>12 months</time_frame>
    <description>AAA maximum diameter in CT scan</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>inflammation markers IL-6</measure>
    <time_frame>12 months</time_frame>
    <description>inflammatory cytokines and parameters of neutrophil activation in patient plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>glucose markers insulin and glucose</measure>
    <time_frame>12 months</time_frame>
    <description>inflammatory cytokines and parameters of neutrophil activation in patient plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neutrophil markers NGAL</measure>
    <time_frame>12 months</time_frame>
    <description>inflammatory cytokines and parameters of neutrophil activation in patient plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ineutrophil marker MPO</measure>
    <time_frame>12 months</time_frame>
    <description>inflammatory cytokines and parameters of neutrophil activation in patient plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neutrophil marker elastase</measure>
    <time_frame>12 months</time_frame>
    <description>inflammatory cytokines and parameters of neutrophil activation in patient plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AAA thrombus</measure>
    <time_frame>12 months</time_frame>
    <description>volume of AAA thrombus</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Abdominal Aortic Aneurysm</condition>
  <arm_group>
    <arm_group_label>INVESTIGATIONAL DRUG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oral metformin treatment with 2000Mg daily: 2x Metformin Hydrochloride 1000Mg Tablet (1-0-1) daily for 1 year</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COMPARATIVE DRUG</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Oral Tablet treatment twice daily (1-0-1) for 1 year</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin Hydrochloride 1000Mg Tablet</intervention_name>
    <description>oral metformin treatment 2x 1000 mg daily (1-0-1) for 1 year</description>
    <arm_group_label>INVESTIGATIONAL DRUG</arm_group_label>
    <other_name>Glucophage (Merck)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Placebo Oral Tablet treatment twice daily (1-0-1) for 1 year</description>
    <arm_group_label>COMPARATIVE DRUG</arm_group_label>
    <other_name>Placebo (Catalent)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        • Infrarenal AAA of 4-5.0 cm maximum diameter

        Exclusion Criteria:

          -  premenopausal female patients with a pregnancy possibility

          -  patients with diabetes

          -  indication for surgical AAA repair

          -  tumor malignancy &lt;1 year, chemotherapy &lt;1 year, hematological disease, chronic
             infectious disease, autoimmune disease and transplant recipients; life expectancy &lt;2
             years

          -  contraindications for metformin, i.e. severly reduced kidney function (eGFR &lt;30
             ml/min), liver dysfunction, pancreatitis, alcohol abusus, malnutrition and
             decompensated heart failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph Neumayer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wolf-Hans Eilenberg, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christine Brostjan, MD, PhD</last_name>
    <phone>+43140400</phone>
    <phone_ext>73514</phone_ext>
    <email>christine.brostjan@meduniwien.ac.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wolf Eilenberg, MD</last_name>
    <phone>+43140400</phone>
    <phone_ext>56200</phone_ext>
    <email>wolf.eilenberg@meduniwien.ac.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of Vienna, Department of Surgery, Division of Vascular Surgery</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wolf Eilenberg, MD</last_name>
      <phone>+43140400</phone>
      <phone_ext>56200</phone_ext>
      <email>wolf.eilenberg@meduniwien.ac.at</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <reference>
    <citation>minimale Endnote Formatierung der Refs im Word Dokument probieren!!!</citation>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2018</study_first_submitted>
  <study_first_submitted_qc>April 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2018</study_first_posted>
  <last_update_submitted>April 14, 2018</last_update_submitted>
  <last_update_submitted_qc>April 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Christoph Neumayer</investigator_full_name>
    <investigator_title>Professor, MD</investigator_title>
  </responsible_party>
  <keyword>abdominal aortic aneurysm</keyword>
  <keyword>metformin</keyword>
  <keyword>non-diabetic</keyword>
  <keyword>placebo</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm, Abdominal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

